Sartorius Stedim: annual net income divided by three
For 2024, the supplier of products and services to the pharmaceutical industry aims to achieve sales growth 'in the mid- to high-single digits', with a current EBITDA margin in excess of 30%.
In the medium term to 2028, the group is targeting average annual sales growth of a percentage 'between the low and mid-teens', as well as a margin increase to over 35%.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction